Effects of encainide and metabolizer phenotype on ventricular conduction during exercise

Dean G. Karalis, Charles Nydegger, R. Stephen Porter, Joseph Carver, Ileana L. Pina, Steven P. Kutalek, Eric L. Michelson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Genetic factors influence the extent of encainide metabolism. Approximately 93% of the Caucasian population extensively metabolize encainide to O-desmethyl encainide (ODE) and 3-methoxy-O-desmethyl encainide (MODE).1 In extensive metabolizers, the steady-state plasma concentrations of ODE and MODE are higher than that of encainide during long-term therapy. In poor metabolizers, the metabolic profile is characterized by high concentrations of encainide, low concentrations of ODE, and absent MODE.2. Encainide can produce marked prolongation of intraventricular conduction and this effect is rate-dependent.3 Previous data indicate that ODE and MODE are more potent than encainide in this regard.4 Consequently, the electropharmacologic effects of encainide would be expected to differ with respect to the genetically determined capacity to metabolize this drug. Thus, we postulated that extensive metabolizers of encainide would show more marked rate-dependent slowing of intraventricular conduction than would poor metabolizers. The present study determines if rate-dependent intraventricular conduction slowing could be demonstrated in patients receiving encainide during exercise-induced sinus tachycardia, and relates this effect to the genetic phenotype of encainide metabolism.

Original languageEnglish (US)
Pages (from-to)1393-1396
Number of pages4
JournalThe American Journal of Cardiology
Volume66
Issue number19
DOIs
StatePublished - Dec 1 1990
Externally publishedYes

Fingerprint

Encainide
Exercise
Phenotype
Sinus Tachycardia
Metabolome
O-demethylencainide

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Karalis, D. G., Nydegger, C., Porter, R. S., Carver, J., Pina, I. L., Kutalek, S. P., & Michelson, E. L. (1990). Effects of encainide and metabolizer phenotype on ventricular conduction during exercise. The American Journal of Cardiology, 66(19), 1393-1396. https://doi.org/10.1016/0002-9149(90)91180-E

Effects of encainide and metabolizer phenotype on ventricular conduction during exercise. / Karalis, Dean G.; Nydegger, Charles; Porter, R. Stephen; Carver, Joseph; Pina, Ileana L.; Kutalek, Steven P.; Michelson, Eric L.

In: The American Journal of Cardiology, Vol. 66, No. 19, 01.12.1990, p. 1393-1396.

Research output: Contribution to journalArticle

Karalis, DG, Nydegger, C, Porter, RS, Carver, J, Pina, IL, Kutalek, SP & Michelson, EL 1990, 'Effects of encainide and metabolizer phenotype on ventricular conduction during exercise', The American Journal of Cardiology, vol. 66, no. 19, pp. 1393-1396. https://doi.org/10.1016/0002-9149(90)91180-E
Karalis, Dean G. ; Nydegger, Charles ; Porter, R. Stephen ; Carver, Joseph ; Pina, Ileana L. ; Kutalek, Steven P. ; Michelson, Eric L. / Effects of encainide and metabolizer phenotype on ventricular conduction during exercise. In: The American Journal of Cardiology. 1990 ; Vol. 66, No. 19. pp. 1393-1396.
@article{51f7c8f5b6b74d50ab7caef6ba027487,
title = "Effects of encainide and metabolizer phenotype on ventricular conduction during exercise",
abstract = "Genetic factors influence the extent of encainide metabolism. Approximately 93{\%} of the Caucasian population extensively metabolize encainide to O-desmethyl encainide (ODE) and 3-methoxy-O-desmethyl encainide (MODE).1 In extensive metabolizers, the steady-state plasma concentrations of ODE and MODE are higher than that of encainide during long-term therapy. In poor metabolizers, the metabolic profile is characterized by high concentrations of encainide, low concentrations of ODE, and absent MODE.2. Encainide can produce marked prolongation of intraventricular conduction and this effect is rate-dependent.3 Previous data indicate that ODE and MODE are more potent than encainide in this regard.4 Consequently, the electropharmacologic effects of encainide would be expected to differ with respect to the genetically determined capacity to metabolize this drug. Thus, we postulated that extensive metabolizers of encainide would show more marked rate-dependent slowing of intraventricular conduction than would poor metabolizers. The present study determines if rate-dependent intraventricular conduction slowing could be demonstrated in patients receiving encainide during exercise-induced sinus tachycardia, and relates this effect to the genetic phenotype of encainide metabolism.",
author = "Karalis, {Dean G.} and Charles Nydegger and Porter, {R. Stephen} and Joseph Carver and Pina, {Ileana L.} and Kutalek, {Steven P.} and Michelson, {Eric L.}",
year = "1990",
month = "12",
day = "1",
doi = "10.1016/0002-9149(90)91180-E",
language = "English (US)",
volume = "66",
pages = "1393--1396",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "19",

}

TY - JOUR

T1 - Effects of encainide and metabolizer phenotype on ventricular conduction during exercise

AU - Karalis, Dean G.

AU - Nydegger, Charles

AU - Porter, R. Stephen

AU - Carver, Joseph

AU - Pina, Ileana L.

AU - Kutalek, Steven P.

AU - Michelson, Eric L.

PY - 1990/12/1

Y1 - 1990/12/1

N2 - Genetic factors influence the extent of encainide metabolism. Approximately 93% of the Caucasian population extensively metabolize encainide to O-desmethyl encainide (ODE) and 3-methoxy-O-desmethyl encainide (MODE).1 In extensive metabolizers, the steady-state plasma concentrations of ODE and MODE are higher than that of encainide during long-term therapy. In poor metabolizers, the metabolic profile is characterized by high concentrations of encainide, low concentrations of ODE, and absent MODE.2. Encainide can produce marked prolongation of intraventricular conduction and this effect is rate-dependent.3 Previous data indicate that ODE and MODE are more potent than encainide in this regard.4 Consequently, the electropharmacologic effects of encainide would be expected to differ with respect to the genetically determined capacity to metabolize this drug. Thus, we postulated that extensive metabolizers of encainide would show more marked rate-dependent slowing of intraventricular conduction than would poor metabolizers. The present study determines if rate-dependent intraventricular conduction slowing could be demonstrated in patients receiving encainide during exercise-induced sinus tachycardia, and relates this effect to the genetic phenotype of encainide metabolism.

AB - Genetic factors influence the extent of encainide metabolism. Approximately 93% of the Caucasian population extensively metabolize encainide to O-desmethyl encainide (ODE) and 3-methoxy-O-desmethyl encainide (MODE).1 In extensive metabolizers, the steady-state plasma concentrations of ODE and MODE are higher than that of encainide during long-term therapy. In poor metabolizers, the metabolic profile is characterized by high concentrations of encainide, low concentrations of ODE, and absent MODE.2. Encainide can produce marked prolongation of intraventricular conduction and this effect is rate-dependent.3 Previous data indicate that ODE and MODE are more potent than encainide in this regard.4 Consequently, the electropharmacologic effects of encainide would be expected to differ with respect to the genetically determined capacity to metabolize this drug. Thus, we postulated that extensive metabolizers of encainide would show more marked rate-dependent slowing of intraventricular conduction than would poor metabolizers. The present study determines if rate-dependent intraventricular conduction slowing could be demonstrated in patients receiving encainide during exercise-induced sinus tachycardia, and relates this effect to the genetic phenotype of encainide metabolism.

UR - http://www.scopus.com/inward/record.url?scp=0025202975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025202975&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(90)91180-E

DO - 10.1016/0002-9149(90)91180-E

M3 - Article

C2 - 2123075

AN - SCOPUS:0025202975

VL - 66

SP - 1393

EP - 1396

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 19

ER -